SCHEMBL1486523

SCHEMBL1486523

CCCCc1nc2cnc3cc(OCc4ccccc4)ccc3c2n1CCOc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.47
HPGD P15428 1/20 0.47
TLR7 Q9NYK1 7/20 0.45
TLR8 Q9NR97 1/20 0.45
TP53 P04637 4/20 0.43
THRB P10828 1/20 0.43
PDE4A P27815 1/20 0.42
PDE4B Q07343 1/20 0.42
PDE4C Q08493 1/20 0.42
PDE4D Q08499 1/20 0.42
MAPT P10636 4/20 0.42
TSHR P16473 3/20 0.41
NPSR1 Q6W5P4 1/20 0.41
ALDH1A1 P00352 1/20 0.41
PKM P14618 1/20 0.41
POLB P06746 1/20 0.40
ADORA3 P0DMS8 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4240323 0.91 TP53 (0.45) SMN1; SMN2HPGDTP53THRBMAPT
SCHEMBL19968181 0.90 TLR7 (0.44) TLR7TLR8PDE4APDE4BPDE4C
SCHEMBL3868318 0.86 RAB9A (0.41) SMN1; SMN2TLR7TLR8TP53MAPT
SCHEMBL6104993 0.85 HPGD (0.58) SMN1; SMN2HPGDTLR7TLR8TP53
SCHEMBL1486493 0.85 CYP3A4 (0.43) HPGDTLR7TLR8TP53MAPT
SCHEMBL1486494 0.85 TLR7 (0.63) TLR7TLR8
SCHEMBL1960376 0.84 SMN1; SMN2 (0.44) SMN1; SMN2HPGDTLR7TLR8TP53
SCHEMBL1486554 0.84 MAPT (0.38) SMN1; SMN2HPGDTLR7TLR8TP53
SCHEMBL4242695 0.81 TLR7 (0.41) TLR7TSHRALDH1A1
SCHEMBL19968462 0.81 TLR7 (0.46) TLR7TLR8PDE4APDE4DTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1658076-B1 ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES CO (US) 2013-03-06 EP disclosed
US-8263594-B2 Aryloxy and arylalkyleneoxy substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-09-11 US disclosed
US-20110144099-A1 ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY 2011-06-16 US disclosed
US-7897597-B2 Aryloxy and arylalkyleneoxy substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2011-03-01 US disclosed
EP-1658076-A4 ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES CO (US) 2009-02-25 EP disclosed
US-20090018122-A1 Aryloxy and Arylalkyleneoxy Substituted Imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2009-01-15 US disclosed
EP-1658076-A1 ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES 3M Innovative Properties Company (US) 2006-05-24 EP disclosed
WO-2005020999-A1 ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018122-A1 Aryloxy and Arylalkyleneoxy Substituted Imidazoquinolines IL2, IFNG, IRF3 SMN1; SMN2 4043/4885HPGD 346/4885TLR7 45/4885
US-20110144099-A1 ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES IL2, IFNG, IRF3 SMN1; SMN2 3907/4885HPGD 410/4885TLR7 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.